64x Bio develops VectorSelect™ cell line engineering platform and AAV Apex Suite to enable scalable, high-yield manufacturing of gene therapies and other advanced biologics. The company is a spinout from Harvard's Wyss Institute and George Church's lab, with Lexi Rovner, PhD as CEO and co-founder. It is based in San Francisco and raised $55 million in Series A funding in 2022.